Beam Therapeutics Inc.
Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using base editing. This assessment focuses on BEAM-302, an in vivo liver-targeted base-editing therapy designed to correct the disease-causing SERPINA1 PiZ mutation in alpha-1 antitrypsin deficiency.
Rare disease / Genetic medicine · In vivo adenine base editing / lipid nanoparticle delivery · Phase 1/2